Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access               Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SRPT message board posts where the ticker symbol SRPT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SRPT SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 5.02
Acc-no: 0001564590-18-030761 (34 Act)  Size: 24 KB
2018-12-11 001-14895
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-061908 Size: 8 KB
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001209191-18-061907 Size: 3 KB
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001193125-18-345018 (33 Act)  Size: 96 KB
2018-12-07 333-228719
8-K  Documents Current report, items 1.01, 8.01, and 9.01
Acc-no: 0001193125-18-323898 (34 Act)  Size: 247 KB
2018-11-09 001-14895
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-323889 (33 Act)  Size: 941 KB
2018-11-09 333-209709
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-008963 (34 Act)  Size: 93 KB
2018-11-09 001-14895
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-18-321739 (33 Act)  Size: 935 KB
2018-11-08 333-209709
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-056987 Size: 9 KB
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-056986 Size: 9 KB
More SRPT SEC Filings

Related news from
Tue, 11 Dec 2018
13:30:00 +0000
Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, announced today that it appointed Mary Ann Gray, Ph.D., to its Board of Directors. Dr. Gray has more than three decades of biotechnology and healthcare experience, with a track record of successfully guiding high-potential companies evolve to their next stage of growth. "We are very pleased to welcome Dr. Gray to Sarepta’s Board of Directors.
Sat, 08 Dec 2018
15:15:43 +0000
Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]
Fri, 07 Dec 2018
13:25:00 +0000
New Research Coverage Highlights Callaway Golf, Synchrony Financial, Roper Technologies, Ringcentral, Sarepta Therapeutics, and Advanced Micro Devices — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Thu, 06 Dec 2018
11:50:00 +0000
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics
NEW YORK, NY / ACCESSWIRE / December 6, 2018 / U.S. markets fell in Tuesday amidst trade related uncertainty between the U.S. and China. The Dow Jones Industrial Average fell 3.10 percent to close at 25,027.07, ...
Tue, 04 Dec 2018
13:05:58 +0000
See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
Sarepta Therapeutics Inc NASDAQ/NGS:SRPT
Fri, 30 Nov 2018
23:00:00 +0000
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2018, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to thirty individuals hired by Sarepta in November 2018. The employees received, in the aggregate, options to purchase 55,270 shares of Sarepta's common stock, and in the aggregate, 16,890 restricted stock units (“RSUs”). The options have an exercise price of $129.47 per share, which is equal to the closing price of Sarepta's common stock on November 30, 2018 (the “Grant Date”).
Thu, 29 Nov 2018
21:45:02 +0000
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.
Thu, 29 Nov 2018
20:14:00 +0000
Wall Street Analysts Are Mostly Positive on BioMarin
BioMarin Pharmaceutical’s net income and EPS for the first nine months of this year amounted to -$73.6 million and -$0.42, respectively, compared to -$65.7 million and -$0.38 in the same period the prior year.
Fri, 23 Nov 2018
14:03:02 +0000
Sarepta Stock More Than Doubles This Year So Far: Here's Why
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.
Fri, 16 Nov 2018
12:00:00 +0000
Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The ...
Mon, 12 Nov 2018
21:21:23 +0000
These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
Novartis and Audentes could hold the keys to curing a pair of genetic diseases — but they will cost $4 million to $5 million apiece, an analyst predicted Monday.
Fri, 09 Nov 2018
00:13:47 +0000
Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, today announced that it has priced an underwritten public offering of an aggregate of 3,817,000 shares of its common stock at a price to the public of $131.00 per share. In addition, Sarepta has granted the underwriters a 30-day option to purchase up to an additional 572,550 shares of its common stock on the same terms and conditions as the initial shares sold to the underwriters. Sarepta anticipates the gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $500,000,000, excluding any exercise of the underwriters’ option to purchase additional shares.
Wed, 07 Nov 2018
21:21:44 +0000
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
Sarepta Therapeutics, Inc. (SRPT), a leader in precision genetic medicine for rare diseases, today announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten public offering. Sarepta also intends to grant the underwriters a 30-day option to purchase an additional $75,000,000 in shares of its common stock offered in the public offering. Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Credit Suisse are acting as joint book-running managers of the proposed offering.
Tue, 06 Nov 2018
15:13:48 +0000
Hedge Funds Just Stormed Into This Red-Hot Biotech Company
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
Tue, 06 Nov 2018
13:43:01 +0000
Implied Volatility Surging for Sarepta Therapeutics (SPRT) Stock Options
Investors need to pay close attention to Sarepta Therapeutics (SPRT) stock based on the movements in the options market lately.
Mon, 05 Nov 2018
15:17:21 +0000
Weekly CEO Buys Highlight
Details the CEO buys this past week from the following companies: Tesla, Sarepta Therapeutics, Hasbro, PacWest Bancorp and Belden
Fri, 02 Nov 2018
16:13:08 +0000
Weekly CFO Sells Highlight
Recent sells from company CFOs

"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is a great group of very smart, sophisticated investors. We have several professionals on board managing millions of dollars, and "average Joe" investors that beat the pants off of Wall Street professionals year in and year out. ValueForum will expose you to a wealth of ideas and sectors, and keep you ahead of the curve." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards